Related Experiment Videos

[Pharmacologic treatment of patent ductus arteriosus in premature infants]

Insights

Oral indomethacin effectively closes large patent ductus arteriosus (DAP) in preterm infants, especially when given early. However, delayed treatment is linked to bronchopulmonary dysplasia and prolonged mechanical ventilation.

Area of Science:

  • Neonatology
  • Pediatric Cardiology

Context:

  • Large patent ductus arteriosus (DAP) is a common complication in preterm infants.
  • Many infants with DAP require mechanical ventilation and have hyaline membrane disease.

Purpose:

  • To evaluate the efficacy of oral indomethacin for pharmacological closure of large DAP in preterm infants.
  • To identify factors influencing treatment response and long-term outcomes.

Summary:

  • Sixty-one preterm infants with large DAP were treated with oral indomethacin.
  • A 64.5% success rate was observed, with younger infants responding better.
  • Long-term survival was 64.5%, with a high incidence of bronchopulmonary dysplasia (BPD) in those receiving later indomethacin treatment.

Impact:

  • Early administration of indomethacin may improve outcomes and reduce the incidence of BPD.
  • Postnatal age at indomethacin treatment correlates with the duration of mechanical ventilation in survivors.

Related Concept Videos